ES2174124T3 - Glutation oxidado como incrementador de la produccion endogena de citoquinas y factores hematopoyeticos. - Google Patents
Glutation oxidado como incrementador de la produccion endogena de citoquinas y factores hematopoyeticos.Info
- Publication number
- ES2174124T3 ES2174124T3 ES96941915T ES96941915T ES2174124T3 ES 2174124 T3 ES2174124 T3 ES 2174124T3 ES 96941915 T ES96941915 T ES 96941915T ES 96941915 T ES96941915 T ES 96941915T ES 2174124 T3 ES2174124 T3 ES 2174124T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutically acceptable
- endogenous production
- salt form
- oxidized
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
Abstract
LA INVENCION ESTA RELACIONADA CON LA MEDICINA, EN PARTICULAR DE LA FARMACOLOGIA Y LA TERAPIA. SEGUN LA INVENCION, SE DESCRIBE UN PROCEDIMIENTO PARA ESTIMULAR LA PRODUCCION ENDOGENA DE CITOCINAS Y FACTORES HEMATOPOYETICOS QUE INCLUYE INTRODUCIR EN UN CUERPO DE UN MAMIFERO QUE NECESITA LA ESTIMULACION DE CITOCINAS O DE FACTOR HEMATOPOYETICO O DE AMBOS, UNA CANTIDAD EFICAZ DE GLUTATION OXIDADO, SU FORMA SALINA FARMACEUTICAMENTE ACEPTABLE Y/O SU DERIVADO FARMACEUTICAMENTE ACEPTABLE, DURANTE UN PERIODO DE TIEMPO PARA ESTIMULAR DICHA PRODUCCION ENDOGENA PARA OBTENER UN EFECTO TERAPEUTICO, SIENDO INTRODUCIDO DICHO GLUTATION OXIDADO, Y/O SU FORMA SALINA FARMACEUTICAMENTE ACEPTABLE, Y/O SU DERIVADO FARMACEUTICAMENTE ACEPTABLE POR VIA PARENTERAL O TOPICA. SEGUN LA INVENCION, SE INTRODUCE EL GLUTATION OXIDADO, Y/O SU FORMA SALINA FARMACEUTICAMENTE ACEPTABLE, Y/O SU DERIVADO FARMACEUTICAMENTE ACEPTABLE, JUNTO CON UN EXTENSOR DE LA SEMIVIDA DE DICHO GLUTATION OXIDADO, Y/O SU FORMA SALINA FARMACEUTICAMENTE ACEPTABLE, Y/O SU DERIVADO FARMACEUTICAMENTE ACEPTABLE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU95120403/14A RU2089179C1 (ru) | 1995-12-14 | 1995-12-14 | Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования |
PCT/RU1996/000226 WO1997021443A1 (en) | 1995-12-14 | 1996-08-08 | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2174124T3 true ES2174124T3 (es) | 2002-11-01 |
Family
ID=26653679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96941915T Expired - Lifetime ES2174124T3 (es) | 1995-12-14 | 1996-12-10 | Glutation oxidado como incrementador de la produccion endogena de citoquinas y factores hematopoyeticos. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0869809B1 (es) |
JP (2) | JP2000515111A (es) |
AT (1) | ATE214936T1 (es) |
AU (1) | AU1113097A (es) |
CA (1) | CA2239874A1 (es) |
DE (1) | DE69620233T2 (es) |
ES (1) | ES2174124T3 (es) |
WO (1) | WO1997021444A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998042363A1 (fr) * | 1997-03-21 | 1998-10-01 | Shiseido Company, Ltd. | Immunostimulants |
IL123887A0 (en) * | 1997-04-02 | 1998-10-30 | Sankyo Co | Dithiolan derivatives their use and pharmaceutical compositions containing the same |
JP2002509715A (ja) * | 1998-03-30 | 2002-04-02 | イ・デ・エム・イミュノ−デジネ・モレキュル | 刺激された単球に由来する細胞、その調製及び用途 |
JP2000169371A (ja) * | 1998-10-02 | 2000-06-20 | Sankyo Co Ltd | ジチオラン誘導体を含有する医薬 |
RU2144374C1 (ru) * | 1998-11-23 | 2000-01-20 | Закрытое акционерное общество "ВАМ" | Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток |
US6312734B1 (en) * | 1998-11-23 | 2001-11-06 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
US20070142267A1 (en) | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
RU2229892C2 (ru) * | 2001-06-08 | 2004-06-10 | Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" | Способ лечения туберкулеза легких |
US7173013B2 (en) | 2001-06-08 | 2007-02-06 | Sciclone Pharmaceuticals, Inc. | Treatment of tuberculosis using immunomodulator compounds |
EP1596756A4 (en) * | 2003-01-23 | 2009-11-11 | Supernus Pharmaceuticals Inc | MEANS TO INCREASE ABSORPTION |
RU2482868C1 (ru) * | 2011-12-30 | 2013-05-27 | Общество С Ограниченной Ответственностью "Ива Фарм" | Средство для лечения диабета, фармацевтическая композиция и способ лечения заболеваний |
EP2900252B1 (en) * | 2012-09-28 | 2017-12-27 | Kyowa Hakko Bio Co., Ltd. | Agent for enhancing immunity containing glutathione |
RU2540500C2 (ru) * | 2013-05-07 | 2015-02-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ прогнозирования ранней стадии апоптоза |
RU2545900C2 (ru) * | 2013-05-07 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ диагностики апоптоза лимфоцитов |
RU2659161C1 (ru) | 2017-11-17 | 2018-06-28 | Общество С Ограниченной Ответственностью "Ива Фарм" | Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид |
CN114617899B (zh) * | 2022-04-14 | 2023-10-20 | 苏州大学附属儿童医院 | S-腺苷甲硫氨酸在制备治疗脓毒血症相关性脑病药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61277619A (ja) * | 1985-06-04 | 1986-12-08 | Otsuka Pharmaceut Factory Inc | 肝疾患治療剤 |
JP2921124B2 (ja) * | 1990-12-28 | 1999-07-19 | 千寿製薬株式会社 | 酸化型グルタチオンアルキルエステル |
US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
US5618823A (en) * | 1992-06-24 | 1997-04-08 | Boehringer Mannheim Italia S.P.A. | Glutathione as chemoprotective agent |
GB9303854D0 (en) * | 1993-02-25 | 1993-04-14 | Holt John A G | Method for enhancing t-cell count |
-
1996
- 1996-12-10 DE DE69620233T patent/DE69620233T2/de not_active Expired - Lifetime
- 1996-12-10 CA CA002239874A patent/CA2239874A1/en not_active Abandoned
- 1996-12-10 ES ES96941915T patent/ES2174124T3/es not_active Expired - Lifetime
- 1996-12-10 EP EP96941915A patent/EP0869809B1/en not_active Expired - Lifetime
- 1996-12-10 JP JP09521965A patent/JP2000515111A/ja not_active Withdrawn
- 1996-12-10 AU AU11130/97A patent/AU1113097A/en not_active Abandoned
- 1996-12-10 AT AT96941915T patent/ATE214936T1/de active
- 1996-12-10 WO PCT/RU1996/000340 patent/WO1997021444A1/en active IP Right Grant
-
2007
- 2007-09-13 JP JP2007238577A patent/JP2008001722A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE214936T1 (de) | 2002-04-15 |
EP0869809B1 (en) | 2002-03-27 |
AU1113097A (en) | 1997-07-03 |
JP2008001722A (ja) | 2008-01-10 |
DE69620233D1 (de) | 2002-05-02 |
JP2000515111A (ja) | 2000-11-14 |
CA2239874A1 (en) | 1997-06-19 |
WO1997021444A1 (en) | 1997-06-19 |
DE69620233T2 (de) | 2002-11-14 |
EP0869809A1 (en) | 1998-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2174124T3 (es) | Glutation oxidado como incrementador de la produccion endogena de citoquinas y factores hematopoyeticos. | |
BR8804370A (pt) | Dispositivo eletroterapeutico de baixa frequencia | |
CY1108629T1 (el) | Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου | |
ES2133413T3 (es) | Gel de lecitina inyectable. | |
ATE241351T1 (de) | Isobutylgaba und dessen derivate zur schmerzbehandlung | |
EA200000282A1 (ru) | Способ введения таксана пациенту, нуждающемуся в лечении таксаном, способ лечения человека таксаном (варианты) | |
GEP20002145B (en) | Stem Cell Factor | |
PT1119393E (pt) | Estimulacao electromagnetica de tecido de cartilagem utilizando fgf | |
DE69621243T2 (de) | Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls | |
ATE198271T1 (de) | Syndecan-stimulierung der zellulären differenzierung | |
IL131478A0 (en) | Methods for treatment of scar tissue | |
JP2016522055A (ja) | 皮膚潰瘍の治療 | |
GB2204497A (en) | Electrode assembly for transdermal drug delivery | |
RU97121729A (ru) | Способ стимуляции репаративного остеогенеза | |
UA39768A (uk) | Спосіб лікування хворих зі спазмом акомодації | |
GB0202410D0 (en) | Treatment of IL deficiencies | |
MD404C2 (ro) | Stimulator aeroionic de modulare | |
UA23878A (uk) | Спосіб лікування поліневропатій, які сполучаються з церебральними судинними дисфункціями | |
CN87106336A (zh) | 同步调频磁疗仪 | |
UA4215U (uk) | Спосіб лікування тунельних нейропатій нижніх кінцівок | |
RU2002113429A (ru) | Способ лечения псориаза | |
UA15068A (uk) | Спосіб відhовлювальhого лікуваhhя хворих дистрофічhими захворюваhhями опорhо-рухового апарату | |
PL295858A1 (en) | Medical catheter with stimulating electrodes in particular for stimulation of hearth | |
UA30659A (uk) | Спосіб купіровання опіатної залежності | |
MX9603833A (es) | Tratamiento mejorado del cancer con temozolomida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 869809 Country of ref document: ES |